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Abstract 
The bone marrow microenvironment plays a key role in the stimulation of growth and survival of 
multiple myeloma (MM) cells. We investigated whether membrane microfragments (MFBs) exert a 
stimulatory effect on mesenchymal stem cell (MSC) gene expression or differentiation. MSCs from 
patients with multiple myeloma (MMBM-MSCs) proliferated at a slower rate than MSCs from 
healthy volunteers (BM-MSCs), and fewer MMBM-MSCs adhered to the substrate as compared to 
BM-MSCs. Phenotypic analysis revealed that MMBM-MSCs and BM-MSCs differed significantly in 
terms of their CD166 and CXCR4 expressions. In conclusion, our comparative analysis of mes-
enchymal cells from MM patients and healthy volunteers revealed differences in the genetic and 
phenotypic profiles of these two populations, their potential for osteodifferentiation, and ex-
pression of surface antigens. Moreover, we showed that membrane MFBs may alter the genetic 
profile of MSCs, leading to disorders of their osteodifferentiation, and interact with the WNT 
pathway via presentation of the DKK-1 protein. 
Key words: bone marrow, genotype, membrane microfragments, microenvironment, multiple 
myeloma, osteodifferentiation 
Introduction 
Multiple myeloma (MM) is an incurable hema-
tologic malignancy of plasma cells that accumulate 
and proliferate in the bone marrow. Most MMs arise 
from bone marrow, which suggests that the bone 
marrow microenvironment plays a key role in the 
stimulation of growth and survival of MM cells [1-2]. 
However, the microenvironmental signals and their 
relevant intracellular messengers, which may serve as 
a potential target for therapeutic intervention, have 
not been fully investigated thus far. Bone marrow 
constitutes a source of mesenchymal stem cells 
(MSCs). MSCs, representing approximately 0.001% of 
all nucleated cells in bone marrow, are a heterogene-
ous population of adult stem cells with a high prolif-
erative potential and the ability to differentiate. 
Friedenstein et al. were the first to isolate and charac-
terize mesenchymal stem cells. They showed that 
MSCs have the potential to differentiate into such 
mesenchymal cell lines as osteocytes, adipocytes and 
chondrocytes [3]. Myeloma cells interact with bone 
marrow microenvironment consisting of endothelial 
cells, stromal cells, mesenchymal cells, osteoclasts, 
osteoblasts, immune cells, adipocytes and extracellu-
lar matrix. These interactions are responsible for 
homing of specific cells in the bone marrow niche, 
their proliferation, survival, and, in the case of MM 
cells, resistance to chemotherapy [4]. Direct contact of 
myeloma cells with the stroma via integrin receptors 
 
Ivyspring  
International Publisher 
 Journal of Cancer 2015, Vol. 6 
 
http://www.jcancer.org 
161 
may be an important factor influencing their prolifer-
ation and survival [2]. The growth of myeloma cells is 
also modulated by cytokines or stromal bone growth 
factors, such as interleukin 6 (IL-6), hepatocyte 
growth factor (HGF), vascular endothelial growth 
factor (VEGF), insulin-like growth factor 1 (IGF-1), 
transforming growth factor-beta (TGF-β) and other 
factors that interfere with bone structure. Uncon-
trolled proliferation of myeloma cells, synthesizing 
excessive amounts of monoclonal immunoglobulins, 
as well as the interaction of these cells with the mi-
croenvironment, cause impairment of the immune 
system and lead to abnormal haematopoiesis, anae-
mia, renal dysfunction, and development of osteolytic 
bone lesions [5-7]. 
Both normal and neoplastic cells exfoliate their 
cellular membranes and secrete circular membrane 
fragments, which are referred to as microfragments 
(MFBs) [8]. MFBs extracted from intact cells are usu-
ally smaller than those from apoptotic cells. The 
amount of secreted MFBs increases during activation 
of cells, hypoxia and radiation damage. The damage 
results from the generation of reactive oxygen species 
and exposure to proteins derived from the activated 
complement cascade [9]. MFBs play an array of func-
tions: they may stimulate other cells by expressing 
“complex signalling” ligands on their surface, deliver 
these ligands to target cells, deliver proteins, mRNA 
and bioactive lipids into target cells, thus transmitting 
infectious particles (e.g. HIV, prions), or perhaps even 
move entire organelles (e.g. mitochondria) to other 
cells [10]. Flow cytometric analysis of the normal and 
neoplastic cell lines showed the presence of small 
structures, which were considered to be fragments of 
cells. The amount of these fragments turned out to be 
specific for a given cell line [11]. Studies using electron 
microscopy demonstrated that these small fragments 
contain many membrane MFBs. Similar processes 
occur both in vitro and in vivo; MFBs released by tu-
mour cells are present both in the microenvironment 
of the tumour and in the peripheral blood [12-16]. 
MFBs were demonstrated to play a significant role in 
lung cancer, particularly by facilitating its growth and 
metastatic potential [17].  
The aim of this study was to evaluate the inter-
action between the bone marrow microenvironment 
and myeloma cells, and analyse the role of MFBs in 
the pathogenesis of MM. 
Materials and Methods 
Ethics 
The study was conducted in accordance with the 
Declaration of Helsinki and approved by the local 
ethics committee. 
Participants 
The study included 20 multiple myeloma pa-
tients (12 men and 8 women) treated at the Haema-
tology Department, University Hospital in Krakow. 
The patients were aged between 45 and 78 years (me-
dian age 64.1 years) and showed bone marrow 
plasmacytosis (15-65%, mean 35.6%). The diagnosis of 
multiple myeloma was based on histological evidence 
of increased fraction of plasma cells in bone marrow 
biopsy specimens ( > 10% plasma cells), and the 
presence of monoclonal protein in blood or urine and 
presence of CRAB criteria [18]. Control group was 
comprised of 10 volunteers (5 men and 5 women) 
aged between 48 and 68 years (median age 64.3 years). 
Bone marrow aspirates from the posterior iliac crest 
were collected to sterile anticoagulant-coated (EDTA 
or heparin) Vacutainer tubes (Becton Dickinson, New 
Jersey, USA). 
Isolation and culture of normal cells 
We isolated bone marrow MSCs from healthy 
donors (BM-MSCs) and from multiple myeloma pa-
tients (MMBM-MSCs). MSCs were isolated according 
to the protocol described by Friedenstein et al. [3] 
Bone marrow mononuclear cells were isolated by 
centrifugation of the total bone marrow on ficoll gra-
dient (1000 x g, 30 min) and subsequent selection via 
adhesion to a plastic surface. 4 x 105/cm2 mononu-
clear cells were seeded into plastic bottles (Sarstedt 
AG & Co., Numbrecht, Germany). Cultures of 
BM-MSCs and MMBM-MSCs were grown on Dul-
becco’s Modified Eagle’s Medium (DMEM, Sig-
ma-Aldrich, Missouri, USA), supplemented with 10% 
fetal bovine serum (FBS) for incubation of MSCs 
(Stem Cell Technologies, Vancouver, Canada). The 
mixture was supplemented with antibiotics (PAA 
Laboratories GmbH, Pasching, Austria) and for 
MMBM-MSCs with IL-6 (2 ng/ml). The cultures were 
incubated at 37°C in an atmosphere of 5% CO2 with 
95% humidity. After reaching 90% density, the cells 
were passaged using 0.05% trypsin (trypsin-EDTA, 
PAA Laboratories GmbH) and seeded into new cul-
ture flasks at 1 x 104/cm2. 
Cell viability during culturing was assessed us-
ing the Trypan Blue Exclusion Test. The MTS test (Cell 
Titer 96 Aqueous One Solution Cell Proliferation As-
say) was performed to assess cells proliferation as per 
manufacturer instructions (Promega, Promega, Mad-
ison, WI, USA). Absorbance was measured using the 
EL800 plate reader (BIO-TEK Instruments, USA) at 
490nm. 
Induction and evaluation of MSC differentia-
tion into osteoblasts 
The role of the bone marrow microenvironment 
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was studied on mesenchymal cell populations that 
had the potential to differentiate into osteogenic cells 
capable of forming the normal structure of bone tis-
sue. BM-MSCs differentiated into osteoblasts after the 
third passage. In preparation for osteoinduction, 3-5 x 
104 cells/well were seeded on 6-well plates and cul-
tured in differentiation medium (DMEM, 10% FBS, 0.1 
mM dexamethasone, 50 g/ml ascorbic acid, and 10 M 
glycerophosphate) for 21 days. The medium was 
changed twice a week. To visualize calcium phos-
phate deposited by osteoblasts, cultures were fixed in 
4% paraformaldehyde (2 min), stained with alizarin 
Red S (Sigma, Missouri, USA) for 2 min, and washed 
with 70% ethanol. Stained calcium phosphate deposits 
were visualized using an Olympus microscope and 
photographed using an Olympus camera. Analogous 
experiments were carried out in the presence of MM 
membrane microfragments (MM-MFBs, 20ng/ml) in a 
differentiating medium. 
Flow cytometric analysis of MSC phenotype 
After the third passage, BM-MSCs and 
MMBM-MSCs were subjected to cytofluorometric 
analysis for the presence of surface antigens common 
to MSCs (CD73, CD166 and CD271) and surface anti-
gens common to hematopoietic lines (CD45, CD34 
and CXCR4). 1 x 105 cells were suspended in 100 ml 
PBS with 2% FBS and stained with the appropriate 
monoclonal antibody (Becton Dickinson) for 30 min at 
4°C in the dark. Subsequently, the cells were har-
vested using a FACS Canto flow cytometer (Becton 
Dickinson) and analysed using FACS Diva software 
(Becton Dickinson). 
Evaluation of gene expression using real-time 
PCR 
After the third passage, MSCs were subjected to 
genotypic analysis with real-time PCR. We deter-
mined expressions of genes for Runx2, PPAR-γ, oste-
ocalcin, collagen-α, matrix metalloproteinase 2 
(MMP-2), matrix metalloproteinase 9 (MMP-9), inter-
leukin 1 (IL-1), interleukin 8 (IL-8), interleukin 11 
(IL-11), TGF-β, HGF, VEGF and β fibroblast growth 
factor (β-FGF). The results were expressed relative to 
the endogenous GADPH control and illustrated in 
arbitrary units. We compared the genotypes of MSCs 
from healthy donors and multiple myeloma patients, 
and analysed expressions of genes in cells exposed to 
membrane MFBs. RNA was isolated using a RNeasy 
Mini Kit (Qiagen, Valencia, CA, USA). The concentra-
tion and purity of the obtained RNA was evaluated by 
measuring absorbance at a 260 nm and 280 nm 
wavelength with a DU 640B spectrophotometer 
(Beckman Coulter, Fullerton, CA, USA). RNA was 
transcribed into cDNA using MMLV reverse tran-
scriptase (Promega, Fitchburg, USA) and random 
primers (Promega). The levels of gene expressions 
were determined by quantitative real-time PCR 
(qRT-PCR) based on the specific TaqMan probe (Ap-
plied Biosystems, Foster City, CA, USA) using a ABI 
PRISM 7300 Sequence Detection System (Applied 
Biosystems). The components of the reaction mixture 
used in the qRT-PCR reaction were: TaqMan PCR 
Master Mix 25 μl, cDNA 100 ng, 20x probe 2.5 μl, 
water added until final volume was 50 μl. Probes used 
for qRT PCR were manufactured by Applied Biosys-
tems accordingly: TaqMan RUNX2 (Hs00231692_ml), 
PPARγ (Hs01115513_ml), HGF (Hs00300159_m1), 
αCOL1 (Hs01076780_ml), OSTEOCALC 
(Hs01587814_ml), PTHR (Hs00896835_ml), MMP-2 
(Hs00234579_m1), MMP-9 (Hs00234579_m1), TGFβ 
(Hs00998133_m1), IL-8 (Hs00174103_m1), IL-11 
(Hs00899845_ml), IL-1 (Hs01055413_ml), VEGF 
(Hs00173626_m1), FGF2/β-FGF (Hs00266645_m1). 
We analysed the relative expression of genes 
expressed as ΔΔCt, being the difference between the 
empiric value and the Ct of the reference gene. 
Isolation of membrane MFBs 
For MFBs isolation, human plasmacytoma lym-
phocyte B cells (U266B1, ATCC TIB-196) were cultured in 
RPMI Medium 1640 (Gibco, BRL, Grand Island NY, 
USA) with 10% FBS, 2 ml L-gluthamine and the fol-
lowing antibiotics: penicillin (100 IU/ml) and strep-
tomycin (100 µg/ml). Cells were maintained at 37oC 
in a humidified atmosphere which contained 5% CO2 
and were seeded into a 6-well plate (Sarsted, Germa-
ny) at a density of 5x105 cells/well in 2mL of medium. 
MFBs released from cellular membranes from 
U266 cells were isolated according to method pro-
posed by Baj-Krzyworzeka et al. 2006 [19]. Superna-
tants from MMBM-MSC cells were collected after 
centrifugation at 2.000g for 20 min. To remove cell 
debris samples were centrifuged again at 50.000g 
(RC28S, Sorvall, Newton, CT, USA) for 1 h at 4oC. 
Pellets were washed several times to remove FBS and 
finally resuspended in serum-free medium. Isolated 
microfragments were thus prepared for further anal-
ysis. 
The effect of stimulation with membrane 
MFBs on MSC gene expression 
To test the effect of MM-MFBs on mesenchymal 
cells, three independent experiments were performed. 
Mesenchymal cells from the third passage were stim-
ulated with MM-MFBs at a concentration of 20 µg/ml, 
and genotypic analysis with real-time PCR was con-
ducted 8, 24 and 48 h after the stimulation. 
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Differentiation of MSCs in the presence or 
absence of membrane MFBs 
To compare the potential of MSCs to differenti-
ate into osteoblasts, the cells from the third passage 
were subjected to osteoinduction. 3-5 x 104 cells/well 
were plated on 6-well plates and cultured for 7, 14 and 
21 days in a differentiation medium containing dex-
amethasone, β-glycerophosphate and ascorbic acid. 
The medium was changed twice a week. After com-
pleting the culture, calcium phosphate deposited by 
the cells was stained with Alizarin Red S. The same 
procedures were carried out in the presence of 
MM-MFBs as well. 
Statistical analysis 
Statistical analysis was conducted with Microsoft 
Excel and GraphPad Prism 4.02 software. The ex-
periments were carried out in at least three iterations. 
Statistical characteristics of quantitative variables are 
presented as arithmetic means with standard devia-
tions or standard errors expressed as error bars on the 
graphs. The information on the number of experi-
ments overall and the number of tests conducted 
during each specific experiment is given below each 
chart. Statistical significance of intergroup difference 
was verified with either the Student-t-test or one-way 
analysis of variance. The threshold of statistical sig-
nificance was set at p<0.05. 
 
 
Figure 1. A. The rate of proliferation of BM-MSCs and MMBM-MSCs. 1-4 
denotes number of cell passages. B. The growth rate of BM-MSCs and 
MMBM-MSCs after 24, 48, 72 and 96 h of cells culturing. 
 
Results 
Characteristics of MSCs 
We observed that the number of MMBM-MSCs 
that adhered to the substrate during culture was 
lower than the respective number of BM-MSCs. 
Moreover, MMBM-MSCs grew at a slower rate than 
the control BM-MSCs (Figure 1 A and B). 
Phenotypic analysis of MSCs 
Both types of MSCs showed similar phenotypes, 
expressing surface antigens CD271 and CD73. How-
ever, MMBM-MSCs and BM-MSCs differed signifi-
cantly in terms of their CD166 and CXCR4 expres-
sions (Figure 2).  
 
 
Figure 2. Comparison of surface antigens expressed by MMBM-MSCs and 
BM-MSCs. Cells were stained using the appropriate antigens and analysed using 
the FACS method. Statistically significant differences were documented for 
CD166 and CXCR4 antigens (n=5, p<0.05). 
 
Genotypic analysis 
MMBM-MSCs showed significantly stronger 
expression of IL-8 and MMP-9 than BM-MSCs. The 
differences in the expressions of TGF-β, IL-1, VEGF 
and PPAR-γ turned out to be insignificant. Addition-
ally, a decrease in the MMBM-MSC expression of 
RUNX2 and α1col was significantly when compared 
with control MSCs (Figure 3). 
Characteristics of membrane MFBs 
The expression of Dikkoph-1 (DKK-1), a protein 
involved in the WNT signalling pathway and bone 
osteolysis, was detected in the protein lysate. Also we 
observed expression of IL-8, VEGF and HGF in the 
MMBM-MSC membrane MFBs (data not shown). 
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Effect of stimulation with MFBs on the ex-
pression of MSC genes 
The levels of BM-MSC gene expressions baseline 
and after 8, 24 and 48 h of stimulation with MM-MFBs 
are presented on Figure 4. The increase in the gene 
expression turned out to be most pronounced after 48 
h of stimulation when statistically significant changes 
in the expressions of genes encoding IL-8, HGF, VEGF 
and β-FGF were documented. 
Differentiation of BM-MSCs in the presence or 
absence of membrane MFBs 
To determine their potential to differentiate, 
BM-MSCs from the third passage were subjected to 
osteoinduction. Neither presence of phosphate de-
posits nor differentiation was observed in the case of 
cells exposed to MM-MFBs, and all these cells even-
tually died (Figure 5). 
 
Figure 3. Genotyping of MMBM-MSCs and BM-MSCs from the third passage. Results were normalized, relative to the GAPDH control. The graphs show the level 
of mRNA for A) IL8, HGF, VEGF and β-FGF, B) TGF-β, IL-1 and IL-11, C) RUNX2, α1col, osteocalcin, PPAR-γ and PTHR, and D) MMP-2 and MMP-9 genes. 
 
Figure 4. Expression of genes in MMBM-MSCs and BM-MSCs after 8-, 24- and 48-h stimulation with MM-MFBs. The cells were grown on 6-well plates in DMEM with 
10% FBS for MSCs, 2 mM L-glutamine and antibiotics. Results were normalized, relative to the GAPDH control. The graphs show the level of mRNA for A) IL8, HGF, 
VEGF and β-FGF, B) TGF-β, IL-1 and IL-11, C) RUNX2, α1col, osteocalcin, PPAR-γ and PTHR, and D) MMP-2 and MMP-9 genes. 
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Figure 5. Osteoinduction of BM-MSCs in the presence of MM-MFBs. The cells from the third passage were cultured for 7, 14 and 21 days in the differentiation 
medium (DMEM with 10% FBS, dexamethasone, β-glycerophosphate and ascorbic acid). Subsequently, the cells were fixed in 4% paraformaldehyde, and calcium 
phosphate deposits were stained with alizarin red S. Legend: + MFB – differentiation in presence of 20 µl/ ml myeloma membrane microfragments, -MFB – differ-
entiation in absence of any additional factors, control – cells that were not subjected to the differentiation. Pictures were taken at a 100 x (A) and 200 x (B) mag-
nification. Representative images are shown. 
 
Discussion 
 In this study, we compared the MSC from 
healthy donors and MM patients in order to under-
stand the mechanisms that are responsible for the 
changes in the bone marrow microenvironment dur-
ing MM progression. We compared the rate of prolif-
eration of MMBM-MSCs and BM-MSCs. The growth 
rate of BM-MSCs turned out to be significantly higher 
than that of MMBM-MSCs. Furthermore, MSCs from 
healthy donors could be maintained in culture for a 
longer period of time and displayed the ability to 
deposit calcium phosphate. Conversely, 
MMBM-MSCs stopped proliferating and died after 
only four passages. 
 The phenotype of MSCs isolated from MM is 
different than in the case of their normal counterparts. 
Our analysis of the antigenic profile of cells from the 
third passage revealed that both MMBM-MSCs and 
BM-MSCs show relatively weak expression of CD271 
and CD73 markers; this finding is consistent with 
previously published data [20-23]. CD166 turned out 
to be significantly decreased on the surface of 
MMBM-MSCs. Furthermore, MSCs showed strong 
expression of CXCR4 receptor. Cytokines play a key 
role in cell homing and migration in MM, among 
them one of the most recognized is stromal 
cell-derived factor 1α (SDF-1α, also known as 
CXCL12) and its receptor CXCR4 [24]. SDF-1α is 
produced by many cells of bone marrow including 
stromal cells, osteblasts and osteoclasts [25]. MM cells 
express SDF-1α and CXCR4 [26], overexpression of 
CXCR4 was confirmed in a number of cancers, in-
cluding MM [27]. It is not fully understood what leads 
to CXCR4 overexpression in tumors, however it is 
postulated that the pro-inflammatory cytokines TNFα 
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[28] and VEGF [29], hypoxia [30] or genetic factors 
[31] may all play a role. CXCR4 expression in MM 
cells has been reported to be inversely correlated with 
disease activity [26]. Wright et al. demonstrated that 
SDF-1α influences osteoclast precursors thus regulat-
ing bone resorption [32]. Inhibition of the 
SDF-1α/CXCR4 axis inhibits osteolysis in animal 
models [33]. The SDF-1α/CXCR4 axis is another po-
tential target for therapy of MM. Compounds which 
are specific inhibitors of CXCR4 tend to hinder the 
process of MM homing [26,34]. Oliveira et al. reported 
that thalidomide down-regulated SDF-1α and CXCR4 
expression in MM patients [35]. Niesvizky et al. 
showed that plasma levels of SDF-1α were signifi-
cantly lower in patients receiving bortezomib, versus 
a non-bortezomib-based therapy [36]. Pandey et al. 
reported suppression of CXCR4 by gambogic acid 
(GA) led to down-regulation of invasion induced by 
the ligand SDF-1α. They found that in MM cells, GA 
suppressed the induction of differentiation of mac-
rophages to osteoclasts in an IL-6 dependent mecha-
nism [27]. Bao et al. reported that CXCR4 is a good 
prognostic indicator of survival in multiple myeloma 
patients [37]. 
 The differences between MSCs derived from the 
BM of newly diagnosed myeloma patients and those 
from healthy donors can give insight into their role in 
the pathophysiology of MM and its consequences. 
Although the potential of MSCs from both origins is 
similar, the functionality and genetic features of MSC 
from MM can differ from their healthy counterparts 
[38]. Garcia-Gomez et al. analyzed the transcriptomic 
profile from both healthy donors and MM patients 
which were co-cultured with myeloma cell line 
MM.1S. Their study confirmed that there was up reg-
ulation in the genetic expression of CXCL1, CXCL5, 
and CXCL6 in both groups, while there was up regu-
lation of the genetic expression of Neuregulin 3 and 
Norrie disease protein exclusively in the MM group 
[39]. CXCL1, CXCL5, and CXCL6 are all important in 
the pathophysiology of MM; several members of the 
CXC family of chemokines act as promoters of angi-
ogenesis [40]. Neuregulin 3 is implicated in normal 
plasma cell differentiation and also in myeloma biol-
ogy [41]. Norrie disease protein is involved in canon-
ical Wntβ/-catenin signaling pathway [42]. 
In this study we analysed the expression of 
genes involved in differentiation of osteocytes, in-
cluding genes active at the early stages of the process, 
such as Runx2 and PPAR-γ, and the genes that are 
specific for the later stages, such as genes for oste-
ocalcin, collagen-1α, MMP-9 and MMP-2, which de-
grade denatured collagen and cell membrane com-
ponents. We also analysed the expression of gene 
encoding IL-11, a cytokine synthesized by osteoblasts, 
eosinophils and stromal cells of bone marrow. Finally, 
we studied the expressions of genes for IL-1, 
pro-inflammatory cytokines, factors associated with 
angiogenesis (IL-8, HGF, VEGF, β-FGF), and TGF-β 
which is involved in the proliferation and differentia-
tion of osteogenic cells. We showed significant dif-
ferences between the gene expression profiles of 
MSCs from bone marrow of MM patients and healthy 
volunteers. MMBM-MSCs were characterized by sig-
nificantly higher transcript levels of IL-8 and MMP-9, 
but significantly lower levels of Runx2 and colla-
gen-1α. These findings are consistent with the results 
published by Todoerti et al., who also showed that the 
the microenvironment of MM patients differs from 
that of healthy donors [43]. Metalloproteinases are 
involved in the degradation of extracellular matrix 
proteins, and MMP-2 and MMP-9 preferentially di-
gest components of the basement membrane. Moreo-
ver, the pro-inflammatory cytokines of MSCs, such as 
TGFβ1, IL-1β and TNFα, were shown to play a vital 
role in the stimulation and expression of MMPs and 
TIMPs [44]. Along with other enzymes, MMP-9 plays 
a role in the metabolism of type IV and V collagen, 
elastin and denatured collagen in normal tissue. 
During inflammation, stimulation by 
pro-inflammatory cytokines can result in a massive 
release of MMPs, including MMP-9, from inflamma-
tory cells. IL-8 is a molecule associated with angio-
genesis. Increased plasma levels of IL-8 were demon-
strated by Kurihara et al., who studied the role of 
various factors (among them IL-6 and VEGF) in he-
matologic malignancies, and their correlation with the 
development of microcirculation [45]. They demon-
strated that the expression of genes involved in oste-
ogenesis, including genes active at the early stages of 
differentiation (i.e., Runx2), was significantly weaker 
in mesenchymal cells originating from MM patients. 
Moreover, they observed decreased expression of 
gene encoding collagen-α, which is normally activat-
ed during the late stages of collagen differentiation. In 
our study, control MSCs showed stronger expressions 
of Runx2, osteocalcin, PPAR-γ and collagen genes, 
which is consistent with the results published by [46], 
who analysed genes involved in bone formation. 
MFBs are important molecules involved in 
transduction of signal between cells, and thereby 
modulate functions of the latter. They activate intra-
cellular signal transduction cascades via MAPK 
p42/44, AKT, and STAT proteins, which results in 
cellular proliferation and inhibition of apoptosis [10]. 
Furthermore, secretion of MFBs by tumour cells leads 
to activation of stromal factors stimulating angiogen-
esis and endothelial cell proliferation. Moreover, 
MFBs are involved in transfer of receptors between 
cells, e.g. in transfer of cell adhesion molecules from 
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platelets to hematopoietic cells, which is reflected by 
enhanced adhesion of the latter to fibrinogen and 
endothelium [47,48]. The transfer of MFBs from acti-
vated platelets to lung cancer cells, results in increase 
adhesion of the latter to endothelium and their ability 
to metastasize in vivo, [17]. Tumour cells coated with 
MFBs that were transplanted into mice demonstrated 
greater metastatic capability than the 
non-encapsulated cells. Higher levels of MFBs in the 
peripheral blood of gastric cancer patients correlated 
with increased metastatic of the tumour and worse 
prognosis [14]. MFBs produced by tumour cells stim-
ulate fibroblasts to secretion of various 
pro-angiogenic factors which act as chemo-attractants 
and enhance proliferation of endothelial cells, thus 
promoting angiogenesis [17]. 
Our analysis of membrane MFBs revealed the 
presence DKK-1 in microfragment protein lysates 
isolated from the supernatant of the U266 MM cell 
line. In the case of MM patients, elevated levels of 
DKK-1 are associated with osteolytic changes [49]. 
Tian et al. demonstrated involvement of DKK-1 in the 
inhibition of osteoblast activity in MM [50]. DKK-1 is 
an important component of the WNT signalling 
pathway and plays an important role in osteodiffer-
entiation. DKK-1 secreted by plasma cells at a con-
centration above 12 ng/ml inhibited osteodifferentia-
tion of murine mesenchymal cells in vitro. Expression 
of the gene transcript for DKK-1 correlated strongly 
with the severity of osteolytic lesions in myeloma pa-
tients [50]. However, other authors did not document 
the presence of DKK-1 in myeloma cells, which sug-
gests that these cells do not universally express this 
protein [51,52]. We demonstrated that myeloma cells 
secrete MFBs containing inhibitors of the WNT 
pathway, the activation of which is required for 
proper development and modelling of skeletal tissue. 
Previous studies revealed that stimulation with MFBs 
alters the cells’ potential to osteodifferentiate. We 
confirmed this observation, staining calcium phos-
phate deposits at 7th, 14th and 21st day of differentia-
tion. In presence of MFBs, the cells did not proliferate 
and completely died after 3 weeks. Staining calcium 
phosphate deposits with von Kossa method con-
firmed that control mesenchymal cells are capable of 
osteodifferentiation. This suggests that myeloma 
MFBs exert negative effect on the bone, via transfer of 
protein inhibitors of the WNT pathway, and points to 
a previously unknown role of membrane microfrag-
ments. 
We revealed that stimulation with MM-MFB al-
ters expression of genes involved in angiogenesis, 
which points to an important role of microfragments 
in cell-to-cell signal transmission. Similar to previous 
studies, we observed a significant, time-dependent 
increase in the expression of IL-8, HGF, VEGF and 
β-FGF after 48 hours of incubation with myeloma 
MFBs. Although the differences in the expression of 
other genes turned out to be statistically insignificant, 
we observed a similar trend as in the comparative 
analysis of MMBM-MSCs and MB-MSCs. Longer ex-
posure of MSCs to membrane MFBs would likely re-
veal the effect of microfragments on the expression of 
genes involved in osteogenesis. 
In conclusion, our comparative analysis of mes-
enchymal cells from MM patients and healthy volun-
teers revealed differences in the genetic and pheno-
typic profiles of these two populations, their potential 
for osteodifferentiation, and expression of surface 
antigens. Moreover, we showed that membrane MFBs 
may alter the genetic profile of MSCs, leading to dis-
orders of their osteodifferentiation, and interact with 
the WNT pathway via presentation of the DKK-1 
protein.  
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